Global Breast Cancer Market 2014-2018


◆タイトル:Global Breast Cancer Market 2014-2018
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:pdf / 英語
Single UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Five UserUSD3,300 ⇒換算¥363,000見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About Breast Cancer
Breast cancer is characterized by the uncontrolled growth of cancerous cells in the breast tissue. It occurs in both males and females; however, male breast cancer is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer and other undifferentiated carcinoma. Ductal carcinoma is the form of breast cancer which starts in the lining of the milk ducts while lobular carcinoma begins in the milk glands of the breast. When breast cancer spreads from the site of origin to surrounding tissue, it is known as invasive breast cancer. Invasive ductal carcinoma is the most common subtype accounting for 70 to 80 percent of all the breast cases. In women, breast cancer is the second most common form of cancer. GLOBOCAN reported that in the year 2012, breast cancer accounted for 11.9 percent of the total cancer cases and lead to 5,22,000 deaths worldwide.
TechNavio’s analysts forecast the Global Breast Cancer market will grow at a CAGR of 11.61 percent over the period 2014-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Breast Cancer market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sale of drugs used for the management of breast cancers including but not limited to:
• HER2-negative breast cancer
• HER2-positive breast cancer
• Hormone receptor positive breast cancer
• Hormone receptor negative breast cancer
• Advanced breast cancer
• Early breast cancer
• Operable node positive breast cancer
• Metastatic breast cancer
• Triple Negative Breast Cancer
The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Global Breast Cancer market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio’s report, the Global Breast Cancer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Breast Cancer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
Key Vendors
• Astrazeneca PLC
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Sanofi-Aventis
Other Prominent Vendors
• Accord Healthcare, Inc.
• Pfizer, Inc.
• Hospira, Inc.
• Actavis, Inc.
• Bayer AG
• BioMarin Pharmaceutical Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation
• Celldex Therapeutics, Inc.
• DARA BioSciences, Inc.
• Eisai Inc.
• Galena Biopharma, Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Hospira, Inc.
• Immunovative Therapies, Ltd
• Nektar Therapeutics
• Nippon Kayaku Co., Ltd
• Pfizer Inc.
• Pierre-Fabre Medicament
• ProStrakan, Inc.
• Pt Dexa Medica
• Sorrento Therapeutics, Inc.
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd

Key Market Driver
• Increase in Breast Cancer Population.
• For a full, detailed list, view our report.
Key Market Challenge
• Poor Diagnosis and Screening.
• For a full, detailed list, view our report.
Key Market Trend
• Increase in Awareness.
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Treatment Regimen for Breast Cancer
08. Market Segmentation by Type of Therapy
09. Market Segmentation by Molecule Type
10. Global Monoclonal Antibodies Market in Breast Cancer
11. Clinical Pipeline Portfolio
12. Geographical Segmentation
12.1 Breast Cancer Drugs Market in the Americas
12.1.1 Market Size and Forecast
12.2 Breast Cancer Drugs Market in the EMEA Region
12.2.1 Market Size and Forecast
12.3 Breast Cancer Drugs Market in the APAC Region
12.3.1 Market Size and Forecast
12.3.2 Country-wise Segmentation of APAC 2013
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2013
20.2.1 F. Hoffmann-La Roche Ltd.
20.2.2 Astrazeneca PLC
20.2.3 Novartis AG
20.2.4 Sanofi-Aventis
20.2.5 Eli Lilly and Company
20.3 Other Prominent Vendors
20.4 Future Players Expected to Tap the Market
21. Key Vendor Analysis

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Breast Cancer Market 2013-2018 (US$ billion)
Exhibit 3: List of Breast Cancer Drugs Served by Other Prominent Players
Exhibit 4: Staging of Breast Cancer Based on Tumor Size and Extent of Metastasis
Exhibit 5: Classification of Breast Cancer Based on Genetic Make-up of Tumor Cells
Exhibit 6: Treatment Regimen for Breast Cancer
Exhibit 7: Global Breast Cancer Market Segmentation by Type of Therapy 2013 (Revenue in Percentage)
Exhibit 8: Molecule Type For Commonly Used APIs in Breast Cancer
Exhibit 9: Global Breast Cancer Drugs Market by Geographical Segmentation 2013
Exhibit 10: Pain Management Drugs Market in the Americas 2013-2018 (US$ billion)
Exhibit 11: Pain Management Drugs Market in the EMEA Region 2013-2018 (US$ billion)
Exhibit 12: Breast Cancer Drugs Market in the APAC Region 2013-2018 (US$ billion)
Exhibit 11: Country-wise Segmentation of APAC 2013 (revenue in percent)
Exhibit 13: 5-Year Survival Rate by Stage of Diagnosis (SEER analysis for 2004-2010)
Exhibit 14: Product Portfolio of Roche’s Breast Cancer Products in US
Exhibit 15: Geography Wise Segmentation for Roche’s Products Used in Breast Cancer (in percent)
Exhibit 16: Product Portfolio of Astrazeneca’s Breast Cancer Products in US
Exhibit 17: Geography Wise Segmentation for Astrazeneca Products Used in Breast Cancer (in percent)
Exhibit 18: Product Portfolio of Novartis’s Breast Cancer Products in US
Exhibit 19: Geography Wise Segmentation for Novartis’s Breast Cancer Products (in percent)


Astrazeneca PLC , Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Novartis AG, Sanofi-Aventis, Accord Healthcare, Inc. , Pfizer, Inc., Hospira, Inc., Actavis, Inc., Bayer AG, BioMarin Pharmaceutical Inc., Bristol-Myers Squibb Company, Celgene Corporation, Celldex Therapeutics, Inc., DARA BioSciences, Inc., Eisai Inc., Galena Biopharma, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Hospira, Inc., Immunovative Therapies, Ltd, Nektar Therapeutics, Nippon Kayaku Co., Ltd, Pfizer Inc. , Pierre-Fabre Medicament , ProStrakan, Inc., Pt Dexa Medica, Sorrento Therapeutics, Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd



★調査レポート[グローバルにおける乳癌治療市場(2014-2018)] (Global Breast Cancer Market 2014-2018 / IRTNTR3609)販売に関する免責事項
[グローバルにおける乳癌治療市場(2014-2018)] (Global Breast Cancer Market 2014-2018 / IRTNTR3609)についてEメールでお問い合わせ